← Amgen overview

Amgen vs Johnson & Johnson: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Amgen Inc (AMGN)

Q3 2026
▲2▼2

Amgen Q3: Pelacarsen Blow Sinks Shares, Recalls and Rival Threats Weigh

  • Pelacarsen failure casts doubt on Amgen's olpasiran Novartis' heart drug pelacarsen failed, and because Amgen's similar olpasiran works the same way, investors feared it could fail too. Shares fell about 10% and BMO downgraded the stock.

    This was the single most severe event of the quarter, directly sinking the share price.

  • Court blocks Colorado's 70% Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, reducing regulatory risk for Amgen's biggest drug. This removes a threat that could have slashed revenue from a key product.

    A major legal win that eased a key overhang on the stock.

  • Q2 beat and raised guidance, key products grow 26% Amgen's Q2 earnings and revenue beat estimates, and the company raised its full-year guidance. Six key products grew 26%, showing the new drug lineup is driving growth.

    Strong financial results and raised outlook support the stock.

  • Recalls, competition, pipeline setback, cyberattack Corlanor and Sensipar recalls raised quality concerns. Merck's cheaper oral PCSK9 threatens Repatha, Sotyktu may erode Otezla, AMG 513 was discontinued, and a cyberattack triggered lawsuits.

    Multiple negative events that weighed on sentiment and future growth prospects.

September 2026
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

Latest
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

August 2026
▲2▼2

Amgen beats Q2, raises guidance, but obesity setback and cyberattack weigh

  • Q2 earnings beat and guidance raise Amgen reported Q2 adjusted EPS of $6.29 and revenue of $10.05B, beating estimates, and raised its 2026 guidance. Six key growth products grew 26%, reducing reliance on older drugs.

    This is a new positive fundamental development that directly supports the stock.

  • Repatha and Tezspire clinical wins Repatha cut death risk by 20% in a major heart trial, and Tezspire met all goals in an eosinophilic esophagitis study. These results lifted shares to a 52-week high and prompted analyst target hikes.

    New clinical data and analyst reactions are key drivers of the stock's move this period.

  • Obesity drug AMG 513 discontinued Amgen discontinued its obesity drug AMG 513, leaving MariTide trailing Eli Lilly and Novo Nordisk in the lucrative obesity market. This raises concerns about Amgen's competitive position.

    This is a new negative event that affects future growth prospects.

  • Cyberattack and drug-price pressure A July cyberattack exposed patient and proprietary data, triggering a class action investigation. Also, a looming US drug-price agreement with mid-sized biotechs could pressure Medicaid revenue.

    These are new risk factors that emerged during the period and could weigh on the stock.

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

  • Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.

    This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.

  • Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.

    New positive trial results expand a key product's potential, a fresh catalyst for the stock.

  • US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.

    This is a new regulatory risk that could directly affect Amgen's pricing and profits.

  • Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.

    This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

  • Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.

    This is the main new positive event that drove the stock up over 5% this period.

  • Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.

    It explains the underlying strength behind the earnings beat and why the stock rose.

  • Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.

    It is a new negative event that could pressure the stock and is important for a balanced view.

  • Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.

    It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 2026
▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

Q2 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

June 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

Johnson & Johnson (JNJ)

Q3 2026
▲3

J&J Beats, Raises Guidance, Settles Talc, But Valuation Stretched

  • Q2 Beat, Guidance Raised, Dividend Hiked J&J beat second-quarter estimates, raised full-year revenue guidance to about $101 billion, and increased its dividend for the 64th straight year, signaling steady profit growth and shareholder returns.

    This is the core new financial update that directly boosted investor confidence in the quarter.

  • $5.5B Talc Settlement Removes Major Legal Overhang A $5.5 billion settlement resolved roughly 76,000 talc claims, removing a large legal cloud that had weighed on the stock and reducing uncertainty about future payouts.

    This is a major new event that reduces a key risk factor for the company.

  • Oncology Strength and New Drug Approvals Strong sales from cancer drugs Darzalex, Tremfya, and Erleada, plus new approvals IMAAVY, ICOTYDE, and THERMOCOOL, support future revenue growth and pipeline momentum.

    These new product successes are a key driver of expected future earnings.

  • Growth Prospects vs. Valuation and Competitive Risks A planned ~$20B DePuy Synthes sale and pipeline deals support growth, but MedTech lagged, Firefly Bio dilutes EPS by ~$0.46, Stelara biosimilar competition accelerates, and rivals beat Tecvayli in myeloma. Valuation trades ~40% above GF Value, limiting upside.

    This captures the main counterweights that could cap gains despite positive developments.

August 2026
▲2▼2

J&J's August–October 2026: New Drug Approvals and Pipeline Gains, but Valuation Stretched

  • New Drug Approvals and Pipeline Expansion J&J won approvals for IMAAVY, China's Icotyde, expanded Stelara use, and the THERMOCOOL catheter, while the OTTAVA surgical robot advanced. These new products strengthen future growth prospects.

    This point highlights the key new product approvals that drove positive sentiment during the period.

  • Oncology Sales Growth and Guidance Raise Oncology sales grew 16%, and J&J raised full-year guidance and lifted its dividend for the 64th straight year. This reflects strong business performance and shareholder returns.

    This point captures the financial performance and guidance that supported the stock.

  • Valuation Stretched Above Fair Value JNJ trades roughly 40% above its GF Value estimate, meaning good news is largely priced in. This limits upside and increases risk of a pullback.

    This point provides a key counterweight, showing the stock may be overvalued.

  • Stelara Biosimilar Competition Accelerates Stelara biosimilar competition is accelerating, slowing overall growth despite new drugs cushioning the impact. Icotyde may also cannibalize Tremfya sales.

    This point highlights a significant headwind that could pressure future revenue.

Latest
▲3

J&J pipeline wins and analyst upgrades offset Stelara biosimilar drag

  • New drug data strengthen growth pipeline J&J reported positive new data for IMAAVY in myasthenia gravis, TECVAYLI/CARVYKTI/TREMFYA in myeloma and arthritis, and two-year ICOTYDE results in psoriasis. These support expanded use and future sales, helping replace revenue lost from older drugs.

    Shows the main new scientific catalysts that can lift future revenue and investor confidence.

  • FDA approves dual-energy heart catheter The FDA approved J&J's THERMOCOOL SMARTTOUCH SF dual-energy catheter, which lets doctors use two energy types in one device. This expands J&J's heart-device lineup and could win share in a growing market, supporting MedTech sales.

    A concrete new product approval that adds a near-term revenue driver in MedTech.

  • Analyst upgrades on defensive appeal and new drugs BofA raised its J&J target to $278, citing a re-rating of defensive stocks and higher ICOTYDE forecasts. Another analyst sees a possible all-time high by year-end. Higher targets can pull more buyers into the stock.

    Captures the main new sell-side actions that influence near-term investor sentiment and demand for the shares.

  • Oncology strength vs. Stelara biosimilar pressure J&J expects strong oncology growth from Darzalex, Carvykti and others, but Stelara's patent expiry is cutting sales faster this quarter, with rivals launching copies. The net effect is slower overall growth, though new drugs are cushioning the blow.

    The key counterweight: it explains why growth is not even faster and keeps the stock from rising more.

September 2026
▲3▼1

J&J advances pipeline and growth plans, but faces competitive setbacks

  • Pipeline and growth outlook strengthened J&J struck a CAR-T deal with Sail Biomedicines, reported positive lung-cancer and depression trial results, and reaffirmed double-digit growth guidance by 2030. These moves bolster future revenue prospects.

    This point highlights new pipeline and guidance developments that could drive future growth.

  • New drug approvals and trial success The FDA approved ICOTYDE for psoriasis, offering a new revenue stream as Stelara loses patent protection. Caplyta met its goal in a bipolar I mania trial, potentially adding up to $5 billion in peak sales.

    These approvals and trial results represent new revenue opportunities for J&J.

  • DePuy Synthes sale to raise cash J&J is nearing a ~$20 billion sale of DePuy Synthes to Apollo, which would raise cash for faster-growing areas. This strategic move could fund future growth initiatives.

    The potential sale is a new strategic action that could impact J&J's capital allocation.

  • Competitive and trial setbacks AbbVie's etentamig beat J&J's Tecvayli in myeloma, rivals are advancing in ulcerative colitis, and a licensed depression drug failed its Phase 2 trial. These setbacks pose risks to J&J's market position.

    These competitive and clinical failures could negatively impact J&J's growth and stock price.

▲3▼1

J&J advances pipeline, nears $20B orthopedics sale

  • FDA approves ICOTYDE for psoriasis The FDA approved ICOTYDE, a once-daily pill for moderate-to-severe plaque psoriasis. This new immunology drug can help replace sales lost from Stelara's patent expiry, adding a fresh revenue stream and supporting J&J's long-term growth.

    New US approval expands J&J's immunology franchise and offsets Stelara loss.

  • Caplyta succeeds in bipolar I mania trial J&J's Caplyta hit its main goal in a late-stage trial for bipolar I mania, with symptom relief seen by day three. If approved, this could add up to $5 billion in peak sales, strengthening J&J's neuroscience business.

    Positive Phase 3 data supports label expansion and potential $5B peak sales.

  • Apollo in talks to buy DePuy Synthes for ~$20B Apollo Global is in talks to buy J&J's orthopedics unit, DePuy Synthes, for close to $20 billion. A sale would give J&J cash to invest in faster-growing areas like oncology and immunology, simplifying the company.

    Potential $20B sale accelerates pivot to higher-growth areas and simplifies J&J.

  • Depression drug fails Phase 2 trial A depression drug J&J licensed, JNJ-5120/PIPE-307, missed its primary goal in a mid-stage trial. This is a setback for J&J's pipeline, though the company is still analyzing the full data before deciding next steps.

    Pipeline setback creates a negative counterweight to the positive pipeline news.

▲1▼1

J&J advances pipeline and weighs $20B orthopedics sale

  • Pipeline and growth outlook strengthen J&J struck a CAR-T deal with Sail Biomedicines, reported strong lung-cancer and depression trial results, and reaffirmed guidance with double-digit growth expected by 2030. These add future sales and support the stock.

    Shows the main positive force behind JNJ's price this period.

  • Possible $20B sale of DePuy Synthes J&J is in talks to sell its orthopedics unit for about $20 billion, but could spin it off or talks could fail. A sale would simplify the company and raise cash, but the outcome is unclear, so the stock impact is uncertain.

    A major capital move that could reshape J&J and affect its price.

  • Competition in myeloma and ulcerative colitis AbbVie's etentamig showed positive Phase 3 results against J&J's Tecvayli, and rivals are advancing in ulcerative colitis. More competition could slow sales of J&J's drugs in these markets.

    A real counterweight to the positive pipeline news.

▲3

J&J wins new drug approvals, but valuation and self-cannibalization temper gains

  • FDA approves IMAAVY as first treatment for warm autoimmune hemolytic anemia The FDA approved J&J's IMAAVY as the first-ever treatment for warm autoimmune hemolytic anemia, a rare blood disease. This opens a brand-new market for a drug already approved for myasthenia gravis, adding future sales and reinforcing J&J's pipeline strength.

    This is a new regulatory approval that expands J&J's addressable market and supports future revenue growth.

  • China approves oral psoriasis drug Icotyde, opening a large market China approved J&J's once-daily oral psoriasis pill Icotyde, targeting over 8.4 million patients there. A pill is more convenient than injections, so it could become a blockbuster and take share from rivals, though it may also pull some patients away from J&J's own injectable Tremfya.

    This is a new geographic approval that opens a major market but carries a self-cannibalization risk.

  • FDA expands Stelara approval to pediatric ulcerative colitis The FDA expanded Stelara's use to children aged two and older with ulcerative colitis. This adds a new patient group for an existing drug, providing a modest sales boost and showing J&J continues to squeeze more value from its older medicines.

    This is a new label expansion that adds a pediatric indication, supporting incremental revenue.

  • New approvals face high valuation and commercial challenges J&J's stock trades about 40% above its GF Value estimate, so good news is already priced in. The new anemia drug faces adoption and reimbursement hurdles, and the China psoriasis pill could just shift sales from Tremfya. These factors limit how much the approvals can lift the stock near term.

    This is the key counterweight: high valuation and commercial execution risks mean the new approvals may not translate into immediate stock gains.

▲4

J&J lifts guidance, raises dividend, expands cancer and device pipeline

  • Guidance raised again on strong Q2 J&J lifted full-year sales guidance to about $101.1 billion and adjusted earnings to $11.68 a share, after quarterly sales of $25.3 billion beat expectations. Higher profit expectations make the stock more attractive and support its price.

    This is the period's core new financial event and directly lifts earnings expectations.

  • Dividend raised for 64th straight year J&J raised its quarterly dividend 3.1% to $1.34 a share, the 64th year in a row, backed by free cash flow that jumped to about $8.7 billion. A growing payout draws income investors and signals confidence in future cash.

    A new dividend increase is a fresh, concrete signal of financial strength that supports the stock.

  • Cancer and device pipeline keeps expanding New wins include European approval of TECVAYLI plus daratumumab for myeloma, FDA clearance for the AI-powered MONARCH QUEST 3 bronchoscopy system, and late-stage development of antidepressant Seltorexant. Each adds future sales and reinforces growth beyond Stelara.

    These are new approvals and pipeline advances that extend J&J's growth story.

  • Underlying growth is double-digit ex-Stelara Reported sales rose 5.6%, but excluding the shrinking Stelara generics drag, growth was double-digit. Tremfya jumped 71% to a first $2 billion quarter, and immunology and neuroscience are becoming new engines. This shows the core business is healthier than the headline.

    It explains why the Stelara patent cliff is no longer the dominant story and supports the bull case.

▲4

Analysts lift JNJ targets as talc deal and cancer sales build

  • Analyst price targets jump after strong Q2 A wave of firms (Scotiabank, Citi, Morgan Stanley, Goldman and others) raised JNJ price targets to roughly $260–$305, lifting the average fair value estimate to about $270.59 from $252.87. Higher targets pull money into the stock and support the share price.

    This is the period's clearest new price driver: broad analyst upgrades after earnings.

  • Talc settlement removes a long-running legal cloud J&J agreed to pay up to $5.5 billion to settle tens of thousands of talc lawsuits, provided at least 95% of claimants accept. Ending years of litigation makes J&J less risky to own and gives investors clearer visibility on future cash costs.

    The settlement is the biggest new event of the period and directly reduces legal risk weighing on the stock.

  • Cancer drug sales keep growing fast J&J's oncology revenue rose 16% to $7.4 billion, led by Darzalex (up about 18% to over $4 billion) and Erleada. Cancer is now nearly 29% of total sales, and J&J targets over $50 billion in annual cancer sales by 2030, supporting long-term growth.

    Oncology is J&J's main growth engine and the fresh sales figures show it is still accelerating.

  • OTTAVA surgical robot seen as a new growth market J&J's FDA-cleared OTTAVA robotic surgery system is being framed as a breakthrough that opens a new device market and could challenge Intuitive Surgical. Investors are watching adoption and orders, which could add a fresh revenue stream over time.

    The robot is a new product story that changes how investors value J&J's device business.

July 2026
▲3▼1

J&J Beats Q2, Raises Guidance, Settles Talc, But MedTech Lags

  • Q2 Beat, Raised Guidance, Dividend Increase J&J beat Q2 estimates for the ninth straight quarter, raised full-year revenue guidance to about $101 billion, and lifted its dividend for the 64th year. This shows steady profit growth and rewards shareholders.

    These are new financial results and capital returns that directly boost investor confidence.

  • Talc Settlement Removes Major Legal Overhang J&J settled about 76,000 talc claims for $5.5 billion, removing a large legal cloud. This reduces uncertainty that had weighed on the stock for years.

    The settlement is a new event that significantly lowers legal risk, a key prior concern.

  • Oncology Strength and Pipeline Expansion Darzalex, Tremfya, and Erleada offset Stelara's patent cliff. FDA clearance of the OTTAVA surgical robot, strong myeloma data, and new cancer deals expand future growth prospects.

    These new product advances and deals drive future revenue and offset patent losses.

  • MedTech Weakness and Firefly Bio EPS Dilution MedTech lagged with Abiomed heart-pump weakness and slowing electrophysiology growth. The Firefly Bio acquisition dilutes 2026 earnings by about $0.46 per share, and an Illinois court upheld a $45 million talc verdict, keeping some legal risk alive.

    These are new negative developments that partially offset the positive news and could pressure the stock.

▲3▼1

J&J settles talc for $5.5B, raises outlook, expands cancer pipeline

  • Talc settlement removes legal overhang J&J agreed to pay $5.5 billion to settle about 76,000 ovarian talc claims, with payments starting no earlier than 2027. This removes a huge legal cloud that had weighed on the stock for years, making J&J less risky to own and lifting shares over 2%.

    This is the single biggest new event of the period and directly reduces JNJ's legal risk, a key overhang.

  • Raised guidance and record Q2 sales J&J posted record quarterly sales of $25.3 billion, up 6.6%, and raised full-year revenue guidance to about $101.1 billion and EPS to $11.68. This puts J&J on track to top $100 billion in annual sales for the first time, boosting confidence in management.

    The raised outlook and record sales are new this period and directly support the stock's long-term value.

  • New cancer pipeline deals and FDA progress J&J partnered with Sail Biomedicines on in vivo CAR-T therapies, completed the $1 billion Firefly Bio acquisition, and won FDA Priority Review for RYBREVANT FASPRO in head and neck cancer. These expand the cancer pipeline and could drive future sales.

    These are new pipeline and regulatory wins that reinforce J&J's oncology growth story.

  • MedTech weakness and Firefly dilution MedTech sales missed estimates as Abiomed's heart pump sales fell 2% after a UK study, and J&J tempered its Abiomed outlook. The Firefly Bio deal will dilute 2026 EPS by about $0.46. These weigh on near-term results and raise doubts about the devices business.

    This is the main counterweight: a real weakness in MedTech and a dilution hit that could pressure the stock.

▲4

J&J's oncology pipeline and surgical robot drive growth

  • FDA clears OTTAVA robotic surgery system J&J won FDA authorization for its OTTAVA robotic surgical system, the first table-integrated soft-tissue robot. This opens a new medical-device growth market and could challenge Intuitive Surgical, adding a fresh revenue stream that supports the stock.

    New regulatory approval creates a new device growth engine, directly answering what is driving JNJ now.

  • TECVAYLI plus TALVEY cuts myeloma death risk 89% A Phase 3 trial showed the TECVAYLI-TALVEY combo cut the risk of progression or death by 89% in earlier-line multiple myeloma. Strong data like this supports wider use and future sales, reinforcing J&J's cancer leadership.

    New clinical data strengthens the oncology pipeline, a key growth driver for JNJ.

  • Oncology sales offset Stelara patent cliff Q2 Innovative Medicine sales rose 6.8% on strong Darzalex, Tremfya and Erleada demand, even as Stelara fell 55% on generics. J&J aims for $50 billion in annual cancer sales by 2030, showing the growth story is intact.

    Explains the core earnings engine and how new drugs are replacing lost revenue, central to JNJ's outlook.

  • Ninth straight earnings beat, guidance raised J&J beat Q2 estimates for the ninth quarter in a row and raised full-year sales and profit guidance, putting it on track to top $100 billion in revenue for the first time. Consistent beats build confidence in management and support the stock.

    Repeated earnings beats and raised guidance are a major reason investors are positive on JNJ right now.

▲3▼1

J&J beats Q2, raises guidance, but MedTech slowdown drags stock

  • Q2 earnings beat and raised 2026 guidance J&J reported Q2 sales of $25.31 billion, up 6.6%, and adjusted EPS of $2.90, both above estimates. It raised full-year revenue guidance to about $101.1 billion and EPS to $11.68. Strong drug sales, especially Tremfya and Darzalex, drove the beat, supporting the stock's long-term value.

    This is the period's biggest new event and directly shows J&J's financial health, a key price driver.

  • MedTech slowdown raises doubts about balanced growth Despite the overall beat, J&J's MedTech unit grew only 3.6% operationally, with cardiovascular sales falling 2% and electrophysiology growth slowing to 3.1%. The stock dropped 2.7% as investors worried that pharma strength is masking weakness in devices, threatening the two-engine growth story.

    This is the main counterweight this period and explains why the stock fell despite the earnings beat.

  • DePuy Synthes acquires Expanding Innovations for spine portfolio J&J's DePuy Synthes acquired Expanding Innovations, adding expandable implant technology for spine surgery. This strengthens its spine portfolio and competitive position in a growing market, supporting future MedTech sales and offsetting some weakness.

    A new acquisition that shows J&J is investing to strengthen its MedTech business, relevant to the growth narrative.

  • Amivantamab projected to lead US EGFR NSCLC revenue by 2036 A forecast shows J&J's amivantamab (with or without lazertinib) generating the highest US revenue in EGFR-mutated lung cancer by 2036, surpassing AstraZeneca's osimertinib. This reinforces J&J's oncology leadership and long-term sales potential.

    New analyst projection that highlights J&J's pipeline strength, a positive for future growth.

▲3▼1

J&J stays out of weight-loss race, boosts dividend, but talc appeal loss stings

  • J&J avoids GLP-1 race, focuses on oncology and devices CEO Joaquin Duato said J&J will not enter the GLP-1 weight-loss drug race, instead focusing on oncology and medical devices where it is strong. This avoids costly competition and supports steady growth, which can lift the stock.

    This is a new strategic decision that affects J&J's competitive position and future growth.

  • J&J raises dividend for 64th straight year and lifts outlook J&J increased its dividend 3.1% to $1.34 per share, marking 64 consecutive years of hikes, and raised full-year revenue guidance to $100.3–$101.3 billion. This signals confidence and appeals to income investors, supporting the stock price.

    This is a new event that directly boosts investor confidence and income appeal.

  • Planned orthopedics spinoff seen as catalyst to boost valuation J&J plans to spin off its DePuy Synthes orthopedics business within 18–24 months. Jim Cramer highlighted this as a catalyst to raise J&J's price-to-earnings multiple, similar to the Kenvue separation. This can unlock value and attract more investors.

    This is a new development that could re-rate the stock and is being actively discussed by influential investors.

  • Illinois court upholds $45 million talc verdict against J&J An Illinois appellate court affirmed a $45 million mesothelioma verdict against J&J and Kenvue, rejecting J&J's appeals. This increases legal risk and potential liabilities from talc lawsuits, which can weigh on the stock price.

    This is a new legal setback that adds to J&J's talc litigation overhang and could pressure the stock.

Q2 2026
▲3▼1

J&J's June: Pipeline Wins, $55B Investment, But CARVYKTI Slows

  • TALVEY Phase 3 Win and European Approval for Tecvayli J&J's TALVEY succeeded in a late-stage multiple myeloma trial, and Tecvayli won European approval. These advances strengthen J&J's cancer drug lineup and support future revenue growth.

    New clinical and regulatory wins are key positive drivers for J&J's growth outlook.

  • $55B U.S. Investment Plan and Firefly Bio Acquisition J&J announced a $55 billion U.S. investment plan aimed at double-digit growth and acquired Firefly Bio for $1 billion. These moves signal confidence and expand its innovative medicine pipeline.

    Major capital commitments and a strategic acquisition are new positive developments for J&J.

  • Talc Lawsuit Victory and Raised 2026 Guidance J&J won a talc lawsuit, reducing legal risk, and raised its 2026 guidance with a $100 billion revenue target. This boosts investor confidence in the company's financial trajectory.

    Legal relief and improved guidance are new positive catalysts for J&J's stock.

  • CARVYKTI Growth Deceleration and Pending Talc Lawsuits CARVYKTI's growth slowed to 57.4% from 63.2%, raising concerns about J&J's premium valuation. Over 67,000 talc lawsuits remain pending, and the stock's modest 6.4% gain suggests investors seek more proof of accelerating growth.

    These are new negative factors that temper the positive outlook and explain the stock's muted reaction.

June 2026
▲3▼1

J&J's June: Pipeline Wins, $55B Investment, But CARVYKTI Slows

  • TALVEY Phase 3 Win and European Approval for Tecvayli J&J's TALVEY succeeded in a late-stage multiple myeloma trial, and Tecvayli won European approval. These advances strengthen J&J's cancer drug lineup and support future revenue growth.

    New clinical and regulatory wins are key positive drivers for J&J's growth outlook.

  • $55B U.S. Investment Plan and Firefly Bio Acquisition J&J announced a $55 billion U.S. investment plan aimed at double-digit growth and acquired Firefly Bio for $1 billion. These moves signal confidence and expand its innovative medicine pipeline.

    Major capital commitments and a strategic acquisition are new positive developments for J&J.

  • Talc Lawsuit Victory and Raised 2026 Guidance J&J won a talc lawsuit, reducing legal risk, and raised its 2026 guidance with a $100 billion revenue target. This boosts investor confidence in the company's financial trajectory.

    Legal relief and improved guidance are new positive catalysts for J&J's stock.

  • CARVYKTI Growth Deceleration and Pending Talc Lawsuits CARVYKTI's growth slowed to 57.4% from 63.2%, raising concerns about J&J's premium valuation. Over 67,000 talc lawsuits remain pending, and the stock's modest 6.4% gain suggests investors seek more proof of accelerating growth.

    These are new negative factors that temper the positive outlook and explain the stock's muted reaction.

▲4

J&J hits record on cancer wins, $1B deal, raised outlook

  • Talc cancer lawsuit win cuts legal risk A Los Angeles jury found J&J not negligent in a talc-cancer case. With over 67,000 similar lawsuits pending, any win lowers the chance of huge payouts and makes the stock less risky to own.

    This is a new legal victory that directly reduces a major overhang on JNJ shares.

  • Firefly Bio acquisition expands cancer pipeline J&J agreed to buy Firefly Bio for $1 billion in cash, gaining a new way to attack cancer cells. This adds to its pipeline and supports its goal of becoming the top cancer company by 2030, which can drive future sales.

    This is a new acquisition that strengthens JNJ's oncology growth story.

  • European approval for Tecvayli combo boosts sales Europe's drug regulator recommended expanding Tecvayli's use in multiple myeloma, based on strong trial results. This makes the drug available to more patients earlier, likely increasing sales and reinforcing J&J's leadership in blood cancer.

    This is a new regulatory win that expands a key drug's market.

  • Raised 2026 outlook and $100B revenue target J&J raised its 2026 revenue growth guidance to 6.1% and says it's on track to hit $100 billion in annual revenue for the first time. This signals confidence in accelerating growth, though the stock has only gained 6.4% since, suggesting investors want more proof.

    This is a new financial outlook that directly addresses JNJ's growth trajectory.

▲3▼1

J&J's oncology pipeline and $55B U.S. investment drive growth outlook

  • TALVEY Phase 3 win in multiple myeloma Positive Phase 3 results for TALVEY plus DARZALEX FASPRO showed superior progression-free survival in multiple myeloma, with up to 72% reduced risk of progression or death. This supports label expansion and could shift treatment guidelines, boosting J&J's oncology franchise and future sales.

    New clinical win directly strengthens J&J's cancer business, a key growth driver.

  • CEO commits $55B U.S. investment, targets double-digit growth CEO Joaquin Duato sees a path to double-digit growth and plans $55 billion in U.S. investment over four years, starting with a new biologics plant. This signals confidence in long-term growth and expands domestic manufacturing, which can lower supply risks and support earnings.

    New capital commitment and growth target show management's strategic direction and confidence.

  • New product launches and data expand treatment options J&J launched a dual-energy catheter ablation platform in Europe and presented new IMAAVY data reinforcing sustained disease control in myasthenia gravis. These advances broaden the medical device and pharma portfolios, supporting future revenue growth.

    New product launches and clinical data are fresh positive developments for J&J's business.

  • CARVYKTI growth deceleration raises valuation concerns CARVYKTI's year-over-year growth slowed to 57.4% from 63.2%, raising questions about its ramp-up. With J&J's stock trading near a 10-year high price-to-sales multiple, any further cooling could pressure the premium valuation and challenge the growth narrative.

    This is a real counterweight: a key growth drug showing slower momentum could weigh on the stock.

© 2026 MarketIVWhy